Literature DB >> 15812483

The process development challenge for a new vaccine.

Barry C Buckland1.   

Abstract

The challenges of vaccine development are not limited to identification of suitable antigens, adjuvants and delivery methods, but include regulatory, technical and manufacturing hurdles in translating a vaccine candidate to the clinic. Process development is the technological foundation that underlies the manufacture of new vaccines and is central to successful commercialization.

Mesh：

Substances：

Year:  2005        PMID： 15812483     DOI： 10.1038/nm1218

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  19 in total

1.  Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.

Authors:  Puneet K Gupta; Paushali Mukherjee; Shikha Dhawan; Alok K Pandey; Suman Mazumdar; Deepak Gaur; S K Jain; Virander S Chauhan
Journal:  Clin Vaccine Immunol       Date:  2014-04-30

2.  The Perennial Use of the Green Fluorescent Protein Marker in a Live Vaccinia Virus Ankara Recombinant Platform Shows No Acute Adverse Effects in Mice.

Authors:  D S O Daian E Silva; T M G Pinho; M A Rachid; D F Barbosa-Stancioli; F G Da Fonseca
Journal:  Braz J Microbiol       Date:  2019-03-15       Impact factor: 2.476

Review 3.  Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Authors:  Michael Schotsaert; Marina De Filette; Walter Fiers; Xavier Saelens
Journal:  Expert Rev Vaccines       Date:  2009-04       Impact factor: 5.217

4.  Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.

Authors:  Melanie Kremer; Yasemin Suezer; Asisa Volz; Theresa Frenz; Monir Majzoub; Kay-Martin Hanschmann; Michael H Lehmann; Ulrich Kalinke; Gerd Sutter
Journal:  PLoS Pathog       Date:  2012-03-01       Impact factor: 6.823

Review 5.  Vaccine hesitancy : Report of a student study group.

Authors:  Lisa Weitz; Luise Bellach; Alicia Faltum; Angelika Berger; Wolfgang Maurer
Journal:  Wien Klin Wochenschr       Date:  2020-04-22       Impact factor: 1.704

6.  Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies.

Authors:  Ashaben Patel; Vineet Gupta; John Hickey; Nancy S Nightlinger; Richard S Rogers; Christine Siska; Sangeeta B Joshi; Michael S Seaman; David B Volkin; Bruce A Kerwin
Journal:  J Pharm Sci       Date:  2018-09-01       Impact factor: 3.534

7.  Multi-epitope-Based Vaccine Designed by Targeting Cytoadherence Proteins of Mycoplasma gallisepticum.

Authors:  Susithra Priyadarshni Mugunthan; Mani Chandra Harish
Journal:  ACS Omega       Date:  2021-05-17

8.  Single dose of multi-clade virus-like particle vaccine protects chickens against clade 2.3.2.1 and clade 2.3.4.4 highly pathogenic avian influenza viruses.

Authors:  Yong-Myung Kang; Hyun-Kyu Cho; Ju Hun Kim; Su Jin Lee; Seo-Jeong Park; Do-Young Kim; Seong Yup Kim; Jung-Won Park; Myoung-Heon Lee; Min-Chul Kim; Hyun-Mi Kang
Journal:  Sci Rep       Date:  2021-07-02       Impact factor: 4.379

9.  Improved Production Efficiency of Virus-Like Particles by the Baculovirus Expression Vector System.

Authors:  Javier López-Vidal; Silvia Gómez-Sebastián; Juan Bárcena; Maria del Carmen Nuñez; Diego Martínez-Alonso; Benoit Dudognon; Eva Guijarro; José M Escribano
Journal:  PLoS One       Date:  2015-10-12       Impact factor: 3.240

10.  Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy.

Authors:  Xia Li; Mohamed A Shenashen; Xiupeng Wang; Atsuo Ito; Akiyoshi Taniguchi; Sherif A Ei-Safty
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.